KareBay has been with small compound custom synthesis business for 6 years, within yearly production capacity over 1 ,000 small compounds; production scales from mg up to Kilograms; Karebay has been serving most of prestigious institutes and universities in the world. Amgene, Celgene, Gentech and most of other top biopharma have been KareBay’s loyal clients already. KareBay has 4 years’ experience in GMP-like small molecule manufacturing, with its own GMP-like production facility.
The founder, Drew Dai did his synthetic chemistry, as part of his PHD dissertation at Univ. of Florida. Later he joined the multimodality molecular imaging group of Eastman Kodak Company’s health group, designing, synthesis, assembly, validation and optimization of various targeting, activatable molecular probes, which was successfully commercialized as animal imaging reagents, now as part of Brukers, the NMR imaging company.
Another key strength of Karebay is organic chemistry (e.g. fluorophore chemistry), solution phase chemistry, polymer chemistry, nanoparticles, besides the well-known solid phase peptide chemistry. The organic combination of such chemistries are critical for building up in vivo molecular imaging probes. Recently KareBay successfully delivered Takeda North America an in vivo pancreatic cancer detection/drug screening imaging probe, now working on granzyme and many other in vivo activatable probes for other companies.
The joint cGMP facility is co-invested and co-operated by KingDay and KareBay. The operation team members are the combination of KareBay’s peptide tech team with Kingday’s USFDA cGMP quality management team. All equipment are directly shipped from KareBay’s GMP like facility. KareBay will also be in charge of the raw materials purchasing from stable, high quality suppliers only.
Kingday, as part of a big pharmaceutical company, Fuan pharmaceutical group in China Stock market, has been with chemical production business for decades. The company has more than 50 platforms loaded with various reactors and GMP rooms on each of both sides of such platforms. Its antibiotics occupies about 1/3 of China market.
How to get started